Pannemans Jasper, Vanuytsel Tim, Tack Jan
Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven University, Leuven, Belgium.
United European Gastroenterol J. 2018 Oct;6(8):1126-1135. doi: 10.1177/2050640618796748. Epub 2018 Aug 27.
Chronic pain affects a large part of the global population, leading to an increase of opioid use. Opioid-induced constipation (OIC), a highly prevalent adverse effect of opioid use, has a major impact on patients' quality of life. Thanks to the introduction of new drugs for chronic constipation, which can also be used in OIC, and the development of peripherally acting mu-opioid receptor blockers, specifically for use in OIC, therapeutic options have seen major development. This review summarises current and emerging treatment options for OIC based on an extensive bibliographical search. Efficacy data for laxatives, lubiprostone, prucalopride, linaclotide, oxycodone/naloxone combinations, methylnaltrexone, alvimopan, naloxegol, naldemedine, axelopran, and bevenopran in OIC are summarised.
慢性疼痛影响着全球很大一部分人口，导致阿片类药物使用量增加。阿片类药物引起的便秘（OIC）是阿片类药物使用中一种非常普遍的不良反应，对患者的生活质量有重大影响。由于可用于慢性便秘且也可用于OIC的新药的推出，以及专门用于OIC的外周作用μ-阿片受体阻滞剂的开发，治疗选择有了重大进展。本综述基于广泛的文献检索总结了OIC目前和新出现的治疗选择。总结了泻药、鲁比前列酮、普芦卡必利、利那洛肽、羟考酮/纳洛酮组合、甲基纳曲酮、阿洛司琼、纳洛戈、纳地美定、阿克洛普仑和贝韦普仑在OIC中的疗效数据。
